This document discusses how analyzing the large amounts of biomedical data now available can help discover new drugs and diagnostics. It notes there are now over 300 trillion points of biomedical data from sources like gene expression studies and electronic health records. The author describes how their research group has used various public big data sources to identify potential new markers for preeclampsia and find that an anti-seizure drug shows activity against inflammatory bowel disease and an anti-depressant against small cell lung cancer in animal models. They discuss the process of moving such findings from initial data analysis to validation and company formation to develop them into new therapies or diagnostics.